3rd Circ. To Review Venue Ruling In GSK Birth Defects Case
By Kelly Knaub (January 27, 2014, 2:52 PM EST) -- The Third Circuit agreed Friday to allow plaintiffs in a suit alleging GlaxoSmithKline PLC's antidepressant drug Paxil caused birth defects to appeal the company's removal of the case to federal court more than a year after the suit began.
Earlier this month, GSK challenged the plaintiffs' Dec. 23 petition for permission to appeal the company's removal of the case to federal court following a landmark Third Circuit ruling in June keeping a separate suit over GSK's morning-sickness drug thalidomide in federal court.
The company argued that there were no exceptional circumstances to warrant an appellate review and that an immediate appeal...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!